Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific ...

French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly could ...

Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...

This article first appeared on GuruFocus. Abivax SA (XPAR:ABVX) is set to release its Q3 2025 earnings on Dec 15, 2025. The ...

Investing.com -- Abivax SA (EPA: ABVX) shares dipped after the company reported a wider net loss for the first nine months ...

Abivax is preparing a regulatory submission in the U.S. in the second half of 2026, provided an ongoing maintenance trial ...

リスク開示書: 金融商品や仮想通貨の取引は投資金額を失う高いリスクがあります。仮想通貨の価格は非常にボラティリティーが高く、金融、規制、政治など、外的な要因に影響を受けることがあります。また信用取引はリスクが高いことを十分に理解して ...

Citizens raised the firm’s price target on Abivax (ABVX) to $131 from $114 and keeps an Outperform rating on the shares. Abivax reported Q3 ...

French biotech company Abivax SA started the year with a market value of less than $500 million. After a meteoric rally, it’s ...

DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, ...

PARIS--(BUSINESS WIRE)--Regulatory News: ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to develop treatments for viral and ...

Abivax CEO Marc de Garidel discusses the future growth of the company, after this year's meteoric rally. Massive data breach ...